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Abstract objectives To investigate the incidence of selected opportunistic infections (OIs) and cancers and
the role of a history of tuberculosis (TB) as a risk factor for developing these conditions in HIV-
infected patients starting antiretroviral treatment (ART) in Southern Africa.
methods Five ART programmes from Zimbabwe, Zambia and South Africa participated. Outcomes
were extrapulmonary cryptococcal disease (CM), pneumonia due to Pneumocystis jirovecii (PCP),
Kaposi’s sarcoma and Non-Hodgkin lymphoma. A history of TB was deﬁned as a TB diagnosis before
or at the start of ART. We used Cox models adjusted for age, sex, CD4 cell count at ART start and
treatment site, presenting results as adjusted hazard ratios (aHR) with 95% conﬁdence intervals (CI).
results We analysed data from 175 212 patients enrolled between 2000 and 2010 and identiﬁed
702 patients with incident CM (including 205 with a TB history) and 487 with incident PCP
(including 179 with a TB history). The incidence per 100 person-years over the ﬁrst year of ART was
0.48 (95% CI 0.44–0.52) for CM, 0.35 (95% CI 0.32–0.38) for PCP, 0.31 (95% CI 0.29–0.35) for
Kaposi’s sarcoma and 0.02 (95% CI 0.01–0.03) for Non-Hodgkin lymphoma. A history of TB was
associated with cryptococcal disease (aHR 1.28, 95% CI 1.05–1.55) and Pneumocystis jirovecii
pneumonia (aHR 1.61, 95% CI 1.27–2.04), but not with Non-Hodgkin lymphoma (aHR 1.09, 95%
CI 0.45–2.65) or Kaposi’s sarcoma (aHR 1.02, 95% CI 0.81–1.27).
conclusions Our study suggests that there may be interactions between different OIs in
HIV-infected patients.
keywords tuberculosis, opportunistic infections, cancer, HIV, risk factors, antiretroviral treatment
programmes, history of tuberculosis
Introduction
HIV-infected patients are at high risk for opportunistic
infections (OIs) such as tuberculosis (TB), cryptococcal
meningitis (CM) and Pneumocystis jirovecii pneumonia
(PCP) (Corbett et al. 2002; Holmes et al. 2003). In many
resource-constrained settings, TB is the most common
AIDS-deﬁning illness, and TB and CM are leading causes
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(ART) in Africa (Lawn et al. 2008; Park et al. 2009).
There may be important interactions between different
HIV-associated opportunistic infections (Corbett et al.
1999, 2002; Havlir & Barnes 1999; Holmes et al. 2003;
Jarvis et al. 2010). HIV replication is inﬂuenced by
co-infections with M. tuberculosis and other opportunis-
tic pathogens due to infection-induced activation of
immune cells, which favours viral replication (Lawn
2004). Furthermore, TB patients often suffer from
impaired pulmonary function after successful treatment
of TB (Pasipanodya et al. 2007; van Zyl Smit et al. 2010;
Ehrlich et al. 2011). It is possible that such damage
facilitates entry of environmental pathogens and their
dissemination in the human body leading to opportunistic
infections (Corbett et al. 2002; Park et al. 2009; Jarvis
et al. 2010).
We analysed a large collaborative dataset of more than
175 000 HIV-infected patients on ART from ﬁve treat-
ment programmes in Southern Africa to study the inci-
dence of respiratory and non-respiratory OIs and the
importance of a history of TB.
Methods
We analysed data from patients enrolled from 1 January
2000 until 1 May 2011 in ﬁve ART programmes partici-
pating in the International epidemiologic Databases to
Evaluate AIDS in Southern Africa (IeDEA-SA, see www.
iedea-sa.org) collaboration in Zimbabwe (Newlands
Clinic, Harare), Zambia (Center for Infectious Disease
Research, CIDRZ, Lusaka) and South Africa (Khayelit-
sha, Tygerberg and Thembalethu ART programmes) (Eg-
ger et al. 2011). IeDEA-SA is part of the IeDEA network,
which includes similar networks in other regions of
Africa, Latin America and the Caribbean, Asia and North
America (see www.iedea.org). Data are collected at each
site as part of routine monitoring at programme enrol-
ment and each follow-up visit. All study sites have local
institutional review board or ethics committee approval
to collect data and participate in IeDEA-SA. We did not
perform any sample size calculations but included all
adult patients (16 years) recorded in the IeDEA-SA
database with a known ART start date from sites that
systematically recorded OI episodes. The selection of eli-
gible patients is shown in Supplementary Figure S1
(online only).
We examined the importance of TB as a risk factor for
the clinically well-deﬁned diseases CM, PCP, Non-Hodg-
kin lymphoma and Kaposi’s sarcoma, based on the
diagnostic criteria used in the treatment programmes. TB
episodes included pulmonary and extrapulmonary
episodes; CM episodes were deﬁned as extrapulmonary
cryptococcal disease and PCP as pneumonia due to P. ji-
rovecii as coded by the sites. History of TB was deﬁned
as a diagnosis before or at start of ART.
We measured follow-up time from the start of ART to
the earliest of either onset of an eligible OI, death or last
follow-up visit. Data were analysed using Cox models
adjusted for age, sex, CD4 cell count at ART initiation
and treatment site to control for between-programme
variations. Because the exposure variable of interest (a his-
tory of TB) is also a stage deﬁning illness (e.g. pulmonary
TB is a WHO stage III disease), we did not adjust for
WHO clinical stage: inclusion of WHO stage would have
biased the estimate for history of TB. In addition, clinical
stages are not consistently reported across programmes.
Incidence was calculated per 100 person-years over the
ﬁrst year of ART. Results are presented as medians with
interquartile ranges (IQR) and crude hazard ratios (HR)
and adjusted hazard ratios (aHR) with 95% conﬁdence
intervals (95% CI). All analyses were performed in STATA
version 11.2 (Stata Corporation, College Station, TX,
USA).
Results
We included 175 212 patients with 320 459 person-years
of follow-up. The largest programme contributing data
was CIDRZ (n = 146 859), followed by Thembalethu
(n = 15 356), Khayelitsha (n = 8173), Tygerberg
(n = 2602) and Newlands (n = 2222). A total of 108 521
patients (61.9%) were women. Median age at ART start
was 35 years (interquartile range [IQR] 29.8–41.6) and
median CD4 cell count 131 cells/lL (IQR 64–205 cells/
lL) (Supplementary Table S1). Overall, 52 062 patients
(31.1%) were lost to follow-up, 1639 (0.9%) transferred
out and 14 409 (8.2%) died. A total of 34 460 patients
(19.7%) had a history of TB; 16 951 (49.2%) of TB
episodes were diagnosed at ART start, 6315 (18.3%)
occurred within 2 years prior to ART start and 11 194
(32.5%) episodes were diagnosed more than 2 years
before the start of ART.
There were 702 patients with incident CM occurring
at or after ART initiation (including 205 with a history
of TB), 487 with incident PCP (including 179 with a his-
tory of TB), 633 with incident Kaposi’s sarcoma (includ-
ing 139 with a history of TB) and 40 patients with an
incident Non-Hodgkin lymphoma (including eight with a
history of TB) (Table 1). The incidence of CM over the
ﬁrst year of ART was 0.48 per 100 person-years (95%
CI 0.44–0.52), PCP incidence during the same period
was 0.35 (95% CI 0.32–0.38), Kaposi’s sarcoma inci-
dence 0.31 (95% CI 0.29–0.35) and Non-Hodgkin
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0.01–0.03).
A history of any TB was associated with CM (aHR
1.28, 95% CI 1.05–1.55) and PCP (aHR 1.61, 95% CI
1.27–2.04). In contrast, a history of TB was not associ-
ated with Non-Hodgkin lymphoma (aHR 1.09, 95% CI
0.45–2.65) or Kaposi’s sarcoma (aHR 1.02, 95% CI
0.81–1.27). Additional analyses showed that a history of
extrapulmonary TB was more strongly associated with
CM than either a history of any TB or a history of pul-
monary TB (Supplementary Table S2, online only). When
excluding patients from the largest ART programme, a
history of any TB remained associated with incident CM
(aHR 1.40, 95% CI 1.03–1.91) and incident PCP (aHR
1.49, 95% CI 1.03–2.17). Low CD4 cell counts were
also a risk factor for CM and PCP (Supplementary Table
2). TB was the most frequent OI with an incidence of
2.19 (95% CI 2.11–2.28) cases per 100 person-years over
the ﬁrst year after ART start.
Discussion
We analysed a large collaborative dataset of HIV-infected
patients starting ART in ﬁve large treatment programmes
in Southern Africa. We found that a history of TB was
associated with both a respiratory and a non-respiratory
OI but not with AIDS-deﬁning cancers.
After successful treatment of TB, many patients have
functional lung impairment and complications such as
bronchiectasis, emphysematous changes and ﬁbrotic
bands (Pasipanodya et al. 2007; Ehrlich et al. 2011).
A study on cryptococcal disease from a cohort in Cape
Town, South Africa, suggested that a history of TB may
be an independent risk factor for subsequent development
of CM, based on 707 patients, of whom 13 developed a
CM episode (Jarvis et al. 2010). Post-TB lung damage
may facilitate entry of the ubiquitously found fungus
C. neoformans into the blood system and its dissemina-
tion. The same may also be true for PCP caused by the
fungus P. jirovecii, which is also found in the environ-
ment (Morris et al. 2002). PCP has previously been
shown to be associated with tobacco use in HIV-infected
patients (Miguez-Burbano et al. 2005), indicating an
association with smoking-induced impaired lung function.
Interestingly, we also found that for CM, the association
was stronger in patients with extrapulmonary TB. These
patients are frequently severely ill with disseminated
disease complicated by acute respiratory distress
syndromes in the lungs (Penner et al. 1995).
Alternatively, the observed association could reﬂect
that patients with more advanced disease (e.g. with a his-
tory of extrapulmonary TB) are at a higher risk for sub-
sequently developing another OI episode (Corbett et al.
2002; Holmes et al. 2003). A history of TB could thus be
a marker for more advanced disease. Adaptive immunity
to M. tuberculosis in humans mainly depends on CD4 T
cells and the mediators interferon-c and tumour necrosis
factor (Ernst 2012). TB infection causes immune activa-
tion, which is associated with disease progression in HIV-
infected patients (Wallis et al. 1993; Shafer & Edlin
1996; Lancioni et al. 2011) and may lead to reduced
immune cell function and immune regulation. Studies
from South Africa, however, failed to show a worse
immunological outcome among patients with TB (Lawn
et al. 2006; Boulle et al. 2010).
A history of TB was not associated with AIDS-deﬁning
cancers in our study. This is reassuring, indicating that
the associations found with CM and PCP may be real,
and not only due to confounding by clinical stage, due to
residual confounding by immunodeﬁciency or due to
closer follow-up and more complete ascertainment of OIs
in patients with a history of TB. However, we stress that
Table 1 Hazard ratios for developing AIDS-deﬁning opportunistic infections and cancers after starting antiretroviral treatment
(ART) in 175 212 HIV-infected patients
Characteristic Total number of events
Association with a history of any TB
HR (95% CI) P-value aHR (95% CI) P-value
AIDS-deﬁning respiratory and non-respiratory opportunistic infections
Cryptococcal meningitis 702 1.64 (1.39–1.93) <0.0001 1.28 (1.05–1.55) 0.015
Pneumocystis jirovecii pneumonia 487 2.34 (1.94–2.81) <0.0001 1.61 (1.27–2.04) <0.0001
AIDS-deﬁning cancers
Non-Hodgkin lymphoma 40 0.92 (0.43–2.01) 0.84 1.09 (0.45–2.65) 0.85
Kaposi’s sarcoma 633 1.05 (0.87–1.27) 0.57 1.02 (0.81–1.27) 0.89
Models were adjusted for age, sex, CD4 cell count at ART start and treatment site. P values are from Wald tests.
ART, antiretroviral therapy; HR, hazard ratios; aHR, adjusted hazard ratios; ND, not deﬁned; TB, tuberculosis; 95% CI, 95%
conﬁdence interval.
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less explain the observed association between a history of
TB and other OIs. For example, conditions such as
silicosis or immunological deﬁcits independent of CD4
cell counts could increase the risk of both TB and other
OIs (Corbett et al. 1999, 2002; Jarvis et al. 2010).
Our study is limited by the potential under-ascertain-
ment of OIs, particularly prior to ART start, due to lack
of laboratory capacities or high costs for tests in some of
the HIV treatment programmes. Indeed, the incidence for
OIs reported in this study was lower compared to other
studies (Corbett et al. 2002; Brinkhof et al. 2007; Fenner
et al. 2011), but as previously reported, the incidence for
TB was higher compared to CM or PCP. In addition, our
results might have been inﬂuenced by the heterogeneous
nature of the ART programmes from three different
countries and the lack of uniform case deﬁnitions and
ascertainment of diagnosis (Fenner et al. 2011). Finally,
our analysis of observational data may be inﬂuenced by
residual confounding and survival bias as the most
severely ill patients may die before ART can be initiated.
However, we adjusted our analyses for the most impor-
tant confounding factors, and we were interested in ratio
measures, rather than absolute differences.
In conclusion, our results suggest a role for interactions
between different OIs in HIV-infected patients. A history
of TB may be a marker for more severe disease and a
worse immune recovery after ART start. It also highlights
the signiﬁcance of post-TB lung disease, which has
received increasing attention over the past few years
(van Zyl Smit et al. 2010; Ehrlich et al. 2011), and its
potential role as a co-factor for OIs. Further research is
needed to study the interactions between TB and other
respiratory and non-respiratory OIs in HIV-infected
patients, with a focus on the mechanisms that underlie
the interactions between OIs and its impact on the
immune recovery after starting ART.
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